Your browser doesn't support javascript.
loading
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Gold, Ralf; Radue, Ernst-Wilhelm; Giovannoni, Gavin; Selmaj, Krzysztof; Havrdova, Eva Kubala; Montalban, Xavier; Stefoski, Dusan; Sprenger, Till; Robinson, Randy R; Fam, Sami; Smith, Jonathan; Chalkias, Spyros; Giannattasio, Giorgio; Lima, Gabriel; Castro-Borrero, Wanda.
Affiliation
  • Gold R; St. Josef-Hospital/Ruhr-University Bochum, 44791, Bochum, Germany. ralf.gold@rub.de.
  • Radue EW; Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland.
  • Giovannoni G; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Selmaj K; Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland.
  • Havrdova EK; Department of Neurology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Montalban X; Hospital Vall d'Hebron University, Barcelona, Spain.
  • Stefoski D; Rush University Medical Center, Chicago, IL, USA.
  • Sprenger T; DKD Helios Klinik Wiesbaden, Wiesbaden, Germany.
  • Robinson RR; AbbVie Inc., Redwood City, CA, USA.
  • Fam S; Biogen, Cambridge, MA, USA.
  • Smith J; Biogen, Maidenhead, UK.
  • Chalkias S; Biogen, Cambridge, MA, USA.
  • Giannattasio G; Biogen, Cambridge, MA, USA.
  • Lima G; Biogen, Cambridge, MA, USA.
  • Castro-Borrero W; Biogen, Cambridge, MA, USA.
J Neurol ; 267(10): 2851-2864, 2020 Oct.
Article in En | MEDLINE | ID: mdl-32451615

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Daclizumab / Immunosuppressive Agents / Multiple Sclerosis Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Language: En Journal: J Neurol Year: 2020 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Daclizumab / Immunosuppressive Agents / Multiple Sclerosis Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Language: En Journal: J Neurol Year: 2020 Document type: Article Affiliation country: Country of publication: